Dec 1, 2020
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With...
1,093
Dec 1, 2020
NCT04352205: Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure
NCT04352205: Phase 2: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure NCT04352205:...
37
Dec 1, 2020
NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in Myeloma or Lymphoma
OPTIMAL-HiChemo NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma...
36
Dec 1, 2020
NCI - National Cancer Institute : How Monoclonal Antibodies Treat Cancer?
How Monoclonal Antibodies Treat Cancer? Daratumumab is a monoclonal antibody against CD38, molecules present on myeloma cancer cells....
198
Dec 1, 2020
NYC-Miami Myeloma MRD 2020 Virtual Meeting, 8th of October 2020
VJHemOnc was official media partner of the NYC-Miami Myeloma MRD 2020 Virtual Meeting which took place on the 8th of October 2020 and was...
73
Dec 1, 2020
EHA25 Virtual : Congress of the European Hematology Association - June 11 - 21, 2020
EHA25 Virtual : Congress of the European Hematology Association, June 11 - 21, 2020 EHA25 Virtual : Congress of the European Hematology...
126
Dec 1, 2020
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
CC-98633 CART NCT04394650: Phase 1 - A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With...
207
Dec 1, 2020
Allogenic CAR T Explained by Precision BioSciences
Allogenic CAR T Explained by Precision BioSciences
91
Dec 1, 2020
FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Velcade & Dexamethasone
FDA Approved for RRMM: : Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Velcade and Dexamethasone FDA approves daratumumab and...
130
Dec 1, 2020
Daratumumab / Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid)+ Dexamethasone for NDMM
NDMM (Transplant ineligible): Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid) & Dexamethasone FDA approves...
119
Dec 1, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial
Publication Newly Diagnosed Multiple Myeloma Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5...
556
Dec 1, 2020
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Myeloma
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma BCMA and CD19 Targeted Fast...
317
Dec 1, 2020
Myeloma UK Publication, intended for UK Audience: Infopack for newly diagnosed patients
Myeloma UK Publication, intended for UK Audience Infopack for newly diagnosed multiple myeloma NDMM https://www.myeloma.org.uk/...
100
Dec 1, 2020
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
D-ClaPd NCT04302324: Phase 2: A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple...
67
Dec 1, 2020
The 20/2/20 risk stratification model for Smoldering Myeloma
Oncologists use 20/2/20 model to calculate risk score to predict progression risk to active myeloma at 2 years for each individual...
3,197
Dec 1, 2020
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple...
142
Dec 1, 2020
Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid) & Dex for RRMM
RRMM: Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid) & Dexamethasone Relapsed & Refractory Multiple...
127
Dec 1, 2020
NCCN GUIDELINES FOR PATIENTS: Immunotherapy Side Effects: Immune Checkpoint Inhibitors
NCCN GUIDELINES FOR PATIENTS: Immunotherapy Side Effects: Immune Checkpoint Inhibitors Click here to see patient's guideline book by...
195
Dec 1, 2020
NCT04499339: Phase 1/2: Autologous SLAMF7 CAR-T Cells in Multiple Myeloma - RRMM - CARAMBA-1
CARAMBA-1 - NCT04499339: Phase 1/2: Autologous SLAMF7 CAR-T Cells in Multiple Myeloma CARAMBA-1 - NCT04499339: Phase 1/2: Autologous...
35